{"id":"https://openalex.org/W7084076216","doi":"https://doi.org/10.69622/29253941.v1","title":"Novel strategies of optimal combinations of targeted therapy in medulloblastoma and neuroblastoma","display_name":"Novel strategies of optimal combinations of targeted therapy in medulloblastoma and neuroblastoma","publication_year":2025,"publication_date":"2025-09-18","ids":{"openalex":"https://openalex.org/W7084076216","doi":"https://doi.org/10.69622/29253941.v1"},"language":"en","primary_location":{"id":"doi:10.69622/29253941.v1","doi":"https://doi.org/10.69622/29253941.v1","is_oa":false,"landing_page_url":"https://doi.org/10.69622/29253941.v1","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Karolinska Institutet","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056421344","display_name":"Monika Lukoseviciute","orcid":"https://orcid.org/0009-0002-3861-2240","observed_orcids":["https://orcid.org/0009-0002-3861-2240"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Monika Lukoseviciute","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5056421344"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.8618000149726868,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.8618000149726868,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.10639999806880951,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.010999999940395355,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/medulloblastoma","display_name":"medulloblastoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/neuroblastoma","display_name":"neuroblastoma","score":1.0},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.9789999723434448},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.722000002861023},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9129999876022339},{"id":"https://openalex.org/keywords/fgfr-inhibitors","display_name":"FGFR inhibitors","score":0.9459999799728394},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/akt-inhibitors","display_name":"AKT inhibitors","score":0.875},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9800000190734863},{"id":"https://openalex.org/keywords/wee1-inhibitor","display_name":"WEE1 inhibitor","score":0.9900000095367432},{"id":"https://openalex.org/keywords/alpelisib","display_name":"alpelisib","score":0.8920000195503235},{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":0.9399999976158142},{"id":"https://openalex.org/keywords/azd5363","display_name":"AZD5363","score":0.8980000019073486},{"id":"https://openalex.org/keywords/mk-1775","display_name":"MK-1775","score":0.996999979019165},{"id":"https://openalex.org/keywords/radiosensitization","display_name":"radiosensitization","score":0.8180000185966492},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.6859999895095825},{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.9309999942779541},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.5519999861717224},{"id":"https://openalex.org/keywords/cell-cycle","display_name":"cell cycle","score":0.6069999933242798}],"concepts":[{"id":"https://openalex.org/C2780789225","wikidata":"https://www.wikidata.org/wiki/Q1333608","display_name":"Medulloblastoma","level":2,"score":0.795199990272522},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7455000281333923},{"id":"https://openalex.org/C2781252693","wikidata":"https://www.wikidata.org/wiki/Q7979264","display_name":"Wee1","level":5,"score":0.6539000272750854},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.6424000263214111},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.6155999898910522},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5758000016212463},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5016000270843506},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4862000048160553},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.4551999866962433},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.37119999527931213},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.3653999865055084},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.352400004863739},{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.3386000096797943},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33719998598098755},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.336899995803833},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.3357999920845032},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.33379998803138733},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.3278000056743622},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32019999623298645},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.31450000405311584},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3034000098705292},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.2987000048160553},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.27959999442100525},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.27619999647140503},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.265500009059906},{"id":"https://openalex.org/C2993561819","wikidata":"https://www.wikidata.org/wiki/Q5097977","display_name":"Pediatric cancer","level":3,"score":0.2596000134944916},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.2540999948978424},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2540999948978424}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.69622/29253941.v1","doi":"https://doi.org/10.69622/29253941.v1","is_oa":false,"landing_page_url":"https://doi.org/10.69622/29253941.v1","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Karolinska Institutet","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/29253941","doi":null,"is_oa":false,"landing_page_url":"https://figshare.com/articles/thesis/Novel_strategies_of_optimal_combinations_of_targeted_therapy_in_medulloblastoma_and_neuroblastoma/29253941","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Thesis"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.6060606837272644,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Background/Aim:":[0],"Medulloblastoma":[1,674],"(MB)":[2],"and":[3,32,40,50,75,91,104,137,147,153,159,168,170,178,182,198,208,223,239,244,286,326,336,371,410,465,472,478,520,533,541,573,588,635,670,700,734,774,778,781,815,819,847],"neuroblastoma":[4,786,823,857],"(NB)":[5],"are":[6],"among":[7,394],"the":[8,35,41,85,124,258,269,273,282,302,312,340,367,391,406,411,427,432,460,523,529,580,583,594,612,625,631,743],"most":[9,252,361,442],"common":[10],"malignant":[11],"solid":[12],"tumors":[13],"in":[14,57,60,67,108,141,209,218,241,309,319,330,416,441,470,481,517,538,563,616,639,672,709,713,737,742,779,784,822,855],"children.":[15],"Despite":[16],"decades":[17],"of":[18,37,127,131,290,369,463,531,585,614,628,643,732,745,772,809],"clinical":[19,82],"advances,":[20],"these":[21,291,509],"cancers":[22],"often":[23,65],"remain":[24],"difficult":[25],"to":[26,29,79,115,375,401,624],"treat":[27],"due":[28],"their":[30],"heterogeneous":[31],"aggressive":[33],"nature,":[34],"emergence":[36],"treatment":[38,591,637,744],"resistance":[39],"toxicity":[42],"associated":[43],"with":[44,184,212,220,268,281,299,311,349,382,431,483,487,497,511,558,703,813,845],"standard":[45,512],"therapies":[46,638],"such":[47,385],"as":[48,206,215,217,278,280,386],"chemotherapy":[49,222,562],"radiotherapy.":[51,224,300],"While":[52],"current":[53],"multimodal":[54],"treatments":[55],"succeed":[56],"improving":[58],"survival":[59,606],"some":[61],"patient":[62],"groups,":[63],"they":[64],"result":[66],"significant":[68],"long-term":[69],"side":[70],"effects.":[71,256,365],"In":[72,118,250,338,359,474,492],"addition,":[73,339],"relapse":[74],"refractory":[76],"disease":[77],"continue":[78],"be":[80],"major":[81],"challenges,":[83],"emphasizing":[84],"urgent":[86],"need":[87,524],"for":[88,525,582,740],"more":[89,586],"effective":[90,317,537],"less":[92,589],"toxic":[93,590],"therapeutic":[94,461],"strategies.":[95,592],"Targeted":[96],"therapies,":[97],"which":[98],"selectively":[99],"inhibit":[100],"key":[101],"oncogenic":[102],"drivers":[103],"molecular":[105],"pathways":[106],"involved":[107],"tumor":[109],"progression,":[110],"offer":[111],"a":[112,856],"promising":[113,490],"alternative":[114],"traditional":[116],"treatments.":[117],"this":[119,577,621],"PHD":[120],"thesis,":[121],"we":[122],"investigated":[123],"preclinical":[125],"efficacy":[126,289],"mostly":[128],"FDA-approved":[129],"inhibitors":[130,185,202,293,373,480,495,501,510,535,560,702,736,776,821,851],"PI3K,":[132,476,662],"FGFR,":[133,663],"CDK4/6,":[134,848],"PARP,":[135],"WEE1":[136,199,303,433,532,735,820],"AKT,":[138],"alone":[139,307,448,546,777],"or":[140,308,352,389,438,486,499,561,704,707,817,849],"various":[142,210],"combinations,":[143],"on":[144,229],"both":[145,205,242,518,570],"MB":[146,161,356,471,519,540],"NB":[148,171,395,422,443],"models":[149],"using":[150],"two-dimensional":[151],"(2D)":[152],"3D":[154,245,575],"cell":[155,162,172,230,236,323,333,357,396,423,444,711,787,824],"culture":[156,246,859],"settings.":[157],"Material":[158],"methods:":[160],"lines":[163,173,324,334,712],"(DAOY,":[164],"UW228-3,":[165],"D425,":[166],"Med8A,":[167],"D283)":[169],"(SK-N-AS,":[174],"SK-N-BE(2)-C,":[175],"SK-N-FI,":[176],"SK-N-DZ,":[177],"SK-N-SH)":[179],"were":[180,203,227],"cultured":[181],"treated":[183],"against":[186],"PI3K":[187,259,370,407,494,559,699,773,814,846],"(BYL719),":[188],"FGFR":[189,274,372,477,498,775,850],"(JNJ-":[190],"42756493),":[191],"CDK4/6":[192,270,412,479,500,664,816],"(PD-0332991),":[193],"AKT":[194,341,551,701],"(AZD5363),":[195],"PARP":[196,313,428,534,544,733,818],"(BMN673)":[197],"(MK-1775).":[200],"The":[201,288],"evaluated":[204],"monotherapies":[207],"combinations":[211,469,601],"each":[213,484],"other,":[214],"well":[216,279],"combination":[219,310,368,482,530],"conventional":[221],"Their":[225],"effects":[226,346,392,419,854],"assessed":[228],"viability,":[231],"growth,":[232],"proliferation,":[233],"cytotoxicity,":[234],"apoptosis,":[235],"cycle":[237],"distribution":[238],"migration":[240],"2D":[243,572],"models.":[247],"Key":[248],"findings:":[249],"MB,":[251,475],"drugs":[253,362],"presented":[254,363],"dose-dependent":[255,364],"Moreover,":[257,366],"inhibitor":[260,271,275,304,314,342,408,413,429,434,468,552],"BYL719":[261,409],"demonstrated":[262,489],"synergistic":[263,345,400,418,439,554,567,853],"anti-tumor":[264,377,505],"activity":[265],"when":[266,297,347,380,556],"combined":[267,298,348,557,810],"PD-0332991,":[272],"JNJ-":[276],"42756493,":[277],"chemotherapeutic":[283,383],"agents":[284,384],"cisplatin":[285,351,706],"vincristine.":[287],"single":[292],"was":[294,316,449,536],"further":[295,526],"enhanced":[296,376],"Notably,":[301,404,528],"MK-1775,":[305],"either":[306],"BMN673,":[315],"specifically":[318],"Sonic":[320],"Hedgehog":[321],"(SHH)-subgroup":[322],"(DAOY":[325],"UW228-3),":[327],"but":[328,608],"not":[329,603],"Group":[331],"3":[332],"(Med8A":[335],"D425).":[337],"AZD5363":[343],"showed":[344,503,547,553],"BYL719,":[350],"vincristine":[353,388,708],"across":[354,420,569],"several":[355],"lines.":[358,424,788,825],"NB,":[360,493,521,542],"led":[374],"efficacy.":[378,491,549],"However,":[379,507],"paired":[381,496],"cisplatin,":[387],"doxorubicin,":[390],"varied":[393],"lines,":[397,445],"ranging":[398],"from":[399],"antagonistic":[402],"responses.":[403],"combining":[405,426,466,508,698],"PD-0332991":[414],"resulted":[415],"consistent":[417],"all":[421],"Similarly,":[425],"BMN673":[430,447],"MK-1775":[435],"produced":[436,514],"additive":[437],"responses":[440,516],"although":[446],"largely":[450],"ineffective.":[451],"Conclusions:":[452],"This":[453],"thesis":[454,622],"provides":[455],"compelling":[456],"pre-clinical":[457],"evidence":[458,629],"supporting":[459,630],"potential":[462],"repurposing":[464],"targeted":[467,695,811,843],"NB.":[473],"other":[485],"radiotherapy":[488],"also":[502,609],"strong":[504],"activity.":[506],"chemotherapeutics":[513],"variable":[515],"highlighting":[522],"investigation.":[527],"SHH":[539,746],"whereas":[543],"inhibition":[545],"limited":[548],"Finally,":[550],"interactions":[555,568],"MB.":[564],"By":[565],"identifying":[566],"simple":[571],"advanced":[574],"models,":[576],"work":[578],"lays":[579],"foundation":[581],"development":[584],"precise":[587],"Crucially,":[593],"findings":[595],"suggest":[596],"that":[597],"rational,":[598],"mechanism-driven":[599],"drug":[600],"may":[602],"only":[604],"enhance":[605],"outcomes":[607],"help":[610],"preserve":[611],"quality":[613],"life":[615],"pediatric":[617,640],"cancer":[618],"patients.":[619],"Overall,":[620],"contributes":[623],"growing":[626],"body":[627],"shift":[632],"towards":[633],"personalized":[634],"mechanism-based":[636],"oncology.":[641],"List":[642],"scientific":[644],"papers":[645],"I.":[646],"Lukoseviciute":[647,684,721,756,796,832],"M,":[648,685,689,722,757,765,797,833],"Maier":[649],"H,":[650],"Poulou-Sidiropoulou":[651],"E,":[652,654,687,801,835],"Rosendahl":[653],"Holzhauser":[655,725,754,798,836],"S,":[656,726,755,799,837],"Dalianis":[657,690,727,768,804,838],"T,":[658,691,728,803,805,839],"Kostopoulou":[659,692,729,766,806,840],"ON.":[660,693,730,807,841],"Targeting":[661],"Signaling":[665],"Pathways":[666],"Together":[667],"With":[668],"Cytostatics":[669],"Radiotherapy":[671],"Two":[673],"Cell":[675],"Lines.":[676],"Front":[677],"Oncol.":[678,791],"2021":[679,792],"Sep":[680],"24;11:748657.":[681],"https://doi.org/10.3389/fonc.2021.748657":[682],"II.":[683],"Need":[686,834],"Birgersson":[688],"Enhancing":[694],"therapy":[696,812,844],"by":[697],"without":[705],"medulloblastoma":[710],"vitro.":[714],"Biomed":[715,861],"Pharmacother.":[716,862],"2024":[717,863],"Nov;180:117500.":[718],"https://doi.org/10.1016/j.biopha.2024.117500":[719],"III.":[720],"Theodosopoulou":[723],"A,":[724],"Combination":[731],"vitro:":[738],"Potential":[739],"use":[741],"medulloblastoma.":[747],"Oncol":[748,826],"Rep.":[749,827],"2023":[750,828],"Jun;49(6):125.":[751],"https://doi.org/10.3892/or.2023.8562":[752],"IV.":[753],"Papachristofi":[758],"C,":[759,761],"Vasilopoulou":[760],"Herold":[762],"N,":[763],"Wickstr\u00f6m":[764],"ON*,":[767],"T":[769],"*.":[770],"Effects":[771],"combination,":[780],"with/without":[782],"cytostatics":[783],"childhood":[785],"Int":[789],"J":[790],"Feb;58(2):211-225.":[793],"https://doi.org/10.3892/ijo.2021.5167":[794],"V.":[795],"Pappa":[800],"Mandal":[802],"Efficacy":[808],"Sep;50(3):166.":[829],"https://doi.org/10.3892/or.2023.8603":[830],"VI.":[831],"Combined":[842],"show":[852],"spheroid":[858],"model.":[860],"Aug;177:116993.":[864],"https://doi.org/10.1016/j.biopha.2024.116993":[865]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2025-10-10T00:00:00"}